Department for Infectious Diseases and Tropical Medicine, Kaiser-Franz-Josef Hospital, Kundratstraße 3, 1100, Vienna, Austria.
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Infection. 2021 Oct;49(5):907-916. doi: 10.1007/s15010-021-01610-z. Epub 2021 May 13.
COVID-19 is regularly compared to influenza. Mortality and case-fatality rates vary widely depending on incidence of COVID-19 and the testing policy in affected countries. To date, data comparing hospitalized patients with COVID-19 and influenza is scarce.
Data from patients with COVID-19 were compared to patients infected with influenza A (InfA) and B (InfB) virus during the 2017/18 and 2018/19 seasons. All patients were ≥ 18 years old, had PCR-confirmed infection and needed hospital treatment. Demographic data, medical history, length-of-stay (LOS), complications including in-hospital mortality were analyzed.
In total, 142 patients with COVID-19 were compared to 266 patients with InfA and 300 with InfB. Differences in median age (COVID-19 70.5 years vs InfA 70 years and InfB 77 years, p < 0.001) and laboratory results were observed. COVID-19 patients had fewer comorbidities, but complications (respiratory insufficiency, pneumonia, acute kidney injury, acute heart failure and death) occurred more frequently. Median length-of-stay (LOS) was longer in COVID-19 patients (12 days vs InfA 7 days vs. InfB 7 days, p < 0.001). There was a fourfold higher in-hospital mortality in COVID-19 patients (23.2%) when compared with InfA (5.6%) or InfB (4.7%; p < 0.001).
In hospitalized patients, COVID-19 is associated with longer LOS, a higher number of complications and higher in-hospital mortality compared to influenza, even in a population with fewer co-morbidities. This data, a high reproduction number and limited treatment options, alongside excess mortality during the SARS-CoV-2 pandemic, support the containment strategies implemented by most authorities.
COVID-19 经常与流感相提并论。死亡率和病死率因 COVID-19 的发病率和受影响国家的检测政策而异。迄今为止,比较 COVID-19 和流感住院患者的数据很少。
将 COVID-19 患者的数据与 2017/18 年和 2018/19 年期间感染甲型流感(InfA)和乙型流感(InfB)病毒的患者进行比较。所有患者年龄均≥18 岁,PCR 检测确诊感染,需要住院治疗。分析人口统计学数据、病史、住院时间(LOS)、包括院内死亡率在内的并发症。
共比较了 142 例 COVID-19 患者、266 例 InfA 患者和 300 例 InfB 患者。观察到年龄中位数(COVID-19 为 70.5 岁,InfA 为 70 岁,InfB 为 77 岁,p<0.001)和实验室结果存在差异。COVID-19 患者合并症较少,但并发症(呼吸衰竭、肺炎、急性肾损伤、急性心力衰竭和死亡)更常见。COVID-19 患者的中位住院时间(LOS)较长(12 天比 InfA 7 天比 InfB 7 天,p<0.001)。与 InfA(5.6%)或 InfB(4.7%)相比,COVID-19 患者的院内死亡率高四倍(23.2%,p<0.001)。
与流感相比,即使在合并症较少的人群中,住院 COVID-19 患者的 LOS 更长、并发症更多、院内死亡率更高。鉴于较高的再感染率和有限的治疗选择,以及 SARS-CoV-2 大流行期间过高的死亡率,支持大多数权威机构实施的遏制策略。